Insulin aspart is an insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. It is available as injection and injectable suspension for subcutaneous and intravenous use. MedsAcross supplies Insulin aspart for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
FIASP is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. • FIASP is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Source: US FDA prescribing information
The primary activity of FIASP is the regulation of glucose metabolism. Insulins, including insulin aspart, the active ingredient in FIASP, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the output of glucose from the liver. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.
Source: US FDA prescribing information
• Individualize and adjust the dosage of FIASP based on route of administration, individual’s metabolic needs, blood glucose monitoring results and glycemic control goal. • Dosage adjustments may be needed when switching from another insulin, with changes in physical activity, changes in concomitant medications, changes in meal patterns, changes in renal or hepatic function or during acute illness. • Subcutaneous injection: o Inject at the start of a meal or within 20 minutes after starting a meal into the abdomen, upper arm, or thigh. o Rotate injection sites within the same region to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. o Should generally be used in regimens with an intermediate- or long-acting insulin. • Continuous Subcutaneous Infusion (Insulin Pump): o Refer to the insulin infusion pump user manual to see if FIASP can be used.
Source: US FDA prescribing information
FIASP is contraindicated: • During episodes of hypoglycemia. • In patients with known hypersensitivity to insulin aspart or any of the excipients in FIASP. • During episodes of hypoglycemia. • Hypersensitivity to insulin aspart or any of the excipients in FIASP.
Source: US FDA prescribing information
• Never share a FIASP FlexTouch pen, PenFill cartridge or PenFill cartridge device between patients, even if the needle is changed. • Hyperglycemia or hypoglycemia with changes in insulin regimen: Make changes to a patient’s insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring. • Hypoglycemia: May be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity, and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness. • Hypoglycemia due to medication errors: Accidental mix-ups between insulin products can occur. Instruct patients to check insulin labels before injection. • Hypokalemia: May be life-threatening.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in labeling: • Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen • Hypoglycemia • Hypokalemia • Hypersensitivity and allergic reactions Adverse reactions observed with FIASP include: hypoglycemia, allergic reactions, hypersensitivity, injection/infusion site reactions, lipodystrophy, and weight gain.
Source: US FDA prescribing information
Table 5 includes clinically significant drug interactions with FIASP. Table 5. Clinically Significant Drug Interactions with FIASP Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose reductions and increased frequency of glucose monitoring may be required when FIASP is co-administered with these drugs.
Source: US FDA prescribing information
Unused FIASP vials should be stored between 2° to 8°C (36° to 46°F) in a refrigerator, but not in or near a freezing compartment. Storage Conditions for Vial, FIASP FlexTouch, PenFill Cartridges and PumpCart Cartridges FIASP presentation Not in-use (unopened) In-use (opened) Room Temperature (up to 30°C [86°F]) Refrigerated (2°C to 8°C [36°F to 46°F]) Room Temperature (up to 30°C [86°F]) Refrigerated (2°C to 8°C [36°F to 46°F]) 10 mL multiple-dose vial 28 days Until expiration date 28 days* (up to 30°C [86°F]) 28 days* 3 mL single-patient-use FIASP FlexTouch pen 28 days Until expiration date 28 days (up to 30°C [86°F]) 28 days 3 mL single-patient-use PenFill cartridges 28 days Until…
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
10 presentations of Insulin aspart, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Novolog 100 IU/mL injectionIntravenous, subcutaneous Cold chain | Novo Nordisk | US FDA | Available on request |
| Insulin aspart 100 IU/mL injectionIntravenous, subcutaneous Cold chainGeneric name | — | US FDA | Available on request |
| NovoLog Mix 70/30 100 IU/mL injectable suspensionSubcutaneous Cold chain | Novo Nordisk Pharmaceutical Industries | US FDA | Available on request |
| Fiasp 100 IU/mL injectionSubcutaneous Cold chain | Novo Nordisk | US FDA | Available on request |
| Insulin Aspart Protamine and Insulin Aspart Mix 70/30 100 IU/mL injectable suspensionSubcutaneous Cold chain | Novo Nordisk Pharma | US FDA | Available on request |
| Kirsty 100 IU/mL injectionIntravenous, subcutaneous Cold chain | Biocon BiologicsIndia | US FDA | Available on request |
| Merilog 100 IU/mL injectionIntravenous, subcutaneous Cold chain | Sanofi-Aventis | US FDA | Available on request |
| .Insulin Aspart Protamine and Insulin Aspart 100 IU/mL injectable suspensionSubcutaneous | A-S Medication Solutions | US FDA | Available on request |
| Garzulys 100 IU/mL injectionSubcutaneous Cold chain | Meitheal Pharmaceuticals | US FDA | Available on request |
| Garzulys 100 IU/mL injectionIntravenous, subcutaneous Cold chain | Meitheal Pharmaceuticals | US FDA | Available on request |
8 brand names across 1 markets.
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Insulin aspart in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 10 presentations of Insulin aspart and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Biocon Biologics.
The catalogue lists 8 brand names for Insulin aspart, including .Insulin Aspart Protamine and Insulin Aspart, Fiasp, Garzulys, Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Kirsty, Merilog, Novolog, NovoLog Mix 70/30.
Yes. The US FDA first approved Insulin aspart on 29 September 2017, according to Drugs@FDA.
Yes. Insulin aspart has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Insulin aspart must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Insulin aspart is classified under ATC code A10AB05 (Insulin aspart).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.